ABSTRACT
To compare multiple doses of insulin and continuous insulin infusion therapy as treatment for type 1 diabetes mellitus. Methods: 40 patients with type 1 diabetes mellitus (21 female) with ages between 10 and 20 years (mean=14.2) and mean duration of diabetes of 7 years used multiple doses of insulin for at least 6 months and after that, continuous insulin infusion therapy for at least 6 months. Each one of the patients has used multiple doses of insulin and continuous insulin infusion therapy. For analysis of HbA1c, mean glycated hemoglobin levels (mHbA1c) were obtained during each treatment period (multiple doses of insulin and continuous insulin infusion therapy period). Results: Although mHbA1c levels were lower during continuous insulin infusion therapy the difference was not statistically significant. During multiple doses of insulin, 14.2% had mHbA1c values below 7.5% vs. 35.71% while on continuous insulin infusion therapy; demonstrating better glycemic control with the use of continuous insulin infusion therapy. During multiple doses of insulin, 1540 patients have severe hypoglycemic events versus 540 continuous insulin infusion therapy. No episodes of ketoacidosis events were recorded. Conclusions: This is the first study with this design comparing multiple doses of insulin and continuous insulin infusion therapy in Brazil showing no significant difference in HbA1c; hypoglycemic events were less frequent during continuous insulin infusion therapy than during multiple doses of insulin and the percentage of patients who achieved a HbA1c less than 7.5% was greater during continuous insulin infusion therapy than multiple doses of insulin therapy.
Comparar terapia com múltiplas doses de insulina e o sistema de infusão continua de insulina no tratamento da diabetes melito tipo 1. Métodos: 40 pacientes com diabetes melito tipo 1 (21 mulheres) com idades entre 10 e 20 anos (média=14,2) e duração média do diabetes de sete anos utilizaram múltiplas doses de insulina durante pelo menos seis meses e, depois disso, sistema de infusão continua de insulina por pelo menos seis meses. Todos os pacientes usaram múltiplas doses de insulina e sistema de infusão continua de insulina. Para a análise de HbA1c, níveis médios de hemoglobina glicada (mHbA1c) foram obtidos em cada período de tratamento (múltiplas doses de insulina e sistema de infusão continua de insulina). Resultados: Embora os níveis de mHbA1c tenham sido menores com o uso de sistema de infusão continua de insulina a diferença não foi estatisticamente significante. Durante o uso de múltiplas doses de insulina, 14,2% tiveram valores de mHbA1c <7,5% vs. 35,71% quando usando sistema de infusão continua de insulina; demonstrando melhor controle glicêmico com o uso de sistema de infusão continua de insulina. Durante o uso de múltiplas doses de insulina, 15-40 pacientes tiveram eventos hipoglicêmicos graves contra 540 com sistema de infusão continua de insulina. Não foram registrados episódios de cetoacidose. Conclusões: Esse é o primeiro estudo cujo desenho comparou o uso de múltiplas doses de insulina e sistema de infusão continua de insulina no Brasil, não demonstrando nenhuma diferença significativa nos níveis de HbA1c. Eventos hipoglicêmicos foram menos frequentes com o uso de sistema de infusão continua de insulina do que com múltiplas doses de insulina e a porcentagem de pacientes que obteve um HbA1c <7,5% foi maior com sistema de infusão continua de insulina do que com múltiplas doses de insulina.
Subject(s)
Humans , Male , Female , Child, Preschool , Child , Adolescent , Young Adult , Diabetes Mellitus, Type 1/drug therapy , Insulin Infusion SystemsABSTRACT
OBJECTIVE: To compare multiple doses of insulin and continuous insulin infusion therapy as treatment for type 1 diabetes melito. METHODS: 40 patients with type 1 diabetes melito (21 female) with ages between 10 and 20 years (mean=14.2) and mean duration of diabetes of 7 years used multiple doses of insulin for at least 6 months and after that, continuous insulin infusion therapy for at least 6 months. Each one of the patients has used multiple doses of insulin and continuous insulin infusion therapy. For analysis of HbA1c, mean glycated hemoglobin levels (mHbA1c) were obtained during each treatment period (multiple doses of insulin and continuous insulin infusion therapy period). RESULTS: Although mHbA1c levels were lower during continuous insulin infusion therapy the difference was not statistically significant. During multiple doses of insulin, 14.2% had mHbA1c values below 7.5% vs. 35.71% while on continuous insulin infusion therapy; demonstrating better glycemic control with the use of continuous insulin infusion therapy. During multiple doses of insulin, 15-40 patients have severe hypoglycemic events versus 5-40 continuous insulin infusion therapy. No episodes of ketoacidosis events were recorded. CONCLUSIONS: This is the first study with this design comparing multiple doses of insulin and continuous insulin infusion therapy in Brazil showing no significant difference in HbA1c; hypoglycemic events were less frequent during continuous insulin infusion therapy than during multiple doses of insulin and the percentage of patients who achieved a HbA1c less than 7.5% was greater during continuous insulin infusion therapy than multiple doses of insulin therapy.
Subject(s)
Diabetes Mellitus, Type 1/drug therapy , Glycated Hemoglobin/analysis , Hypoglycemic Agents/therapeutic use , Insulin Infusion Systems , Insulin/therapeutic use , Adolescent , Brazil , Child , Diabetes Mellitus, Type 1/blood , Female , Humans , Hypoglycemia/chemically induced , Hypoglycemic Agents/adverse effects , Insulin/adverse effects , Longitudinal Studies , Male , Young AdultABSTRACT
Juvenile nasopharyngeal angiofibroma (JNA) is a vascular tumor of the nasopharynx that accounts for 0.5% of all cancers of the head and neck. It primarily affects males aged 14-25 years. Of the many genes that mediate the development of JNA, GSTM1 has been most frequently associated with this vascular tumor. The loss of expression of GSTM1 (null genotype) is linked to the development of these tumors. The aim of this cross-sectional case study was to examine the prevalence of the GSTM1-null genotype in Brazilian patients with JNA. DNA was extracted from the leukocytes of blood samples from 10 patients. GSTM1 genotypes were analyzed using a PCR-based assay that was designed to identify the wild-type allele of GSTM1. All 10 patients (100%) were males, with a mean age of 17.8 years. The null genotype for GSTM1 was noted in 4 patients (40%)-1 (10%) at Fisch stage I, 1 (10%) at stage III, and 2 (20%) at stage II. No patient with this genotype had stage IV disease. There was no correlation between Fisch classification and GSTM1 genotype (P = .5695). The correlation between age at diagnosis and GSTM1 genotype was not significant (P = .728). The present findings indicate that there is evidence of an association between the GSTM1-null genotype and JNA in this studied Brazilian population.
